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Total nitric oxide production is low in patients with chronic
renal disease1
REBECCA J. SCHMIDT and CHRIS BAYLIS
Departments of Medicine and Physiology, West Virginia University School of Medicine, Morgantown, West Virginia, USA
Total nitric oxide production is low in patients with chronic (arginine) deficiency [3] caused by a loss of functional
renal disease. renal mass, increased endogenous NO synthase (NOS)
Background. A deficiency of the endogenous vasodilator inhibitors that accumulate in renal failure [2], and/ornitric oxide (NO) has been implicated as a potential cause of
other causes, such as increased oxidant stress [4]. Inhypertension in chronic renal disease (CRD) patients. This
study was conducted to determine whether 24-hour NOX (NO2 addition to being caused by CRD, low NO production
and NO3) excretion (a qualitative index of total NO production) may contribute to and/or exacerbate the progression of
is reduced in patients with CRD. CRD by both hemodynamic and renal growth-promot-Methods. Measurements were made in 13 CRD patients and
ing actions [5].9 normotensive healthy controls after 48 hours on a controlled
low-NOX diet. Urine was collected over the second 24-hour The plasma concentration and urinary excretion of NO2
period for analysis of 24-hour NOX, and cGMP and blood drawn and NO3 (NOX; the stable oxidation products of NO)
at the completion. Plasma levels of arginine (the substrate for are now being widely used to give a measure of totalendogenous renal NO synthesis), citrulline (substrate for renal
NO production in vivo. In rats with subtotal nephrec-arginine synthesis), and the endogenous NO synthesis inhibitor
asymmetrical dimethylarginine (ADMA) and its inert isomer tomy, 24-hour NOX excretion is reduced [6–8], suggesting
and symmetrical dimethylarginine (SDMA) were also deter- reduced total NO production (assuming that NOX intake
mined. is constant). Reduced urinary NOX excretion has alsoResults. Systolic blood pressure was higher in CRD patients
been reported in children with CRD [9], in adults with(12 of whom were already on antihypertensive therapy) than
in controls (P , 0.05). Twenty-four–hour urinary NOX excre- IgA nephropathy and hypertension [10], and in adults
tion was low in CRD patients compared with controls despite with CRD caused by a variety of causes [11]. Although
similar dietary NO intake, suggesting that net endogenous NO suggestive of decreased total NO production in CRD,production is decreased in renal disease. In contrast, the 24-
one concern is that no clinical study to date has employedhour urinary cGMP did not correlate with UNOXV. Plasma ci-
trulline was increased in CRD patients, possibly reflecting re- dietary control with a low NOX intake. As we have dis-
duced conversion of citrulline to arginine. Plasma arginine was cussed previously, controlled NOX intake is essential for
not different, and plasma ADMA levels were elevated in CRD interpretation of NOX excretion data [12]. Accordingly,versus controls, changes that would tend to lower NO synthase.
we conducted the present study during low and con-Conclusion. These results suggest that NO production is
low in CRD patients and may contribute to hypertension and trolled dietary NOX intake to determine whether 24-
disease progression in CRD. hour NOX excretion (a qualitative index of total NO
production) is reduced in patients with CRD of various
etiologies.
It has been suggested that the physiologically impor-
tant vasodilator nitric oxide (NO) is deficient in chronic
progressive renal disease (CRD) and in end-stage renal METHODS
failure (ESRD) [1, 2]. This could result from substrate Thirteen CRD patients were asked to participate in
the study. Nine normotensive, healthy subjects were re-
1 See Editorial by Ketteler and Ritz, p. 1356 cruited from spouses of CRD patients and from West
Virginia University Health Science Center faculty, stu-Key words: arginine, hypertension, vasodilation, blood pressure, kid-
ney failure, oxidation. dents, and staff to serve as the control group. Controls
were required to be normotensive with no known ill-
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Table 1. Demographic and clinical characteristics of the study population
CRD patient # Age Sex BSA CCr Disease Medications
1 29 M 1.67 46 SK None
2 51 M 2.22 23 Wegener’s BB, CCB, MIN
3 56 M 1.75 23 CIN CAD, CCB, D
4 58 M 2.30 19 GN BB, CCB, CAD
5 62 F 2.59 46 DM BB, CEI, D
6 63 F 2.60 31 DM CEI, D
7 65 M 2.10 32 FSGS CAD, CCB, D
8 67 M 1.92 40 DM CEI, D
9 74 F 1.81 28 DM CCB, D
10 78 M 1.84 19 DM D
11 59 M 2.24 46 IgA1SK CEI
12 32 F 1.34 10 Obstr Nephr CEI
13 67 M 2.19 44 IgA CEI, D
All CRD (N 5 13) 5964 4F:9M 2.0460.10 3163a
CRD subgroup (N 5 6) 5767 2F:4M 1.9860.18 3366a 3DM, 1 SK, 1 IgA 1
SK, Obstr Nephr
Control (N 5 9) 5966 5F:4M 2.0760.11 124621 None None
Twelve of 13 CRD patients were on one or more antihypertensive agents. Abbreviations are: BB, beta blocker; CAD, centrally acting adrenergic blocker; CCB,
calcium channel blocker; CEI, angiotensin-converting enzyme inhibitor; D, diuretic; MIN, minoxidil; M, male; F, female; FSGS, focal and segmental glomerulosclerosis;
SK, solitary kidney; CIN, chronic interstitial nephritis; GN, glomerulonephritis; DM, diabetic nephropathy; Obstr Nephr, obstructive nephropathy; CCr, creatinine
clearance; BSA, body surface area. Patients on nitrates were excluded from the study.
aP , 0.05 vs. control
on one or more antihypertensive medications (Table 1); with the phosphodiesterase inhibitor 3-isobutyl-1-meth-
ylxanthine (IBMX; 30 mL of 10 mmol/L IBMX to 500however, no patient was on nitrates.
All participants were provided with complete meals mL plasma) to prevent the breakdown of cGMP in vitro.
containing low NOX (330 mmol/day, approximately 25%
Analysesof normal daily dietary NO3 intake) [13]. Supplemental
calories, if required, were provided in the form of zero The following analyses were conducted: NOX concen-
NOX, zero sodium content foods. Subjects were given tration of plasma and urine was measured using the
verbal and written instructions at the beginning of the Griess assay after conversion of NO3 to NO2 with the
diet period, and were instructed to eat only what food NO3 reductase enzyme, as we previously described [14].
was provided during this period and to report any un- Plasma and urine cGMP were measured by the Cayman
eaten food. Subjects were again questioned at the end of Chemicals ELISA kit. Plasma arginine and citrulline
the 48-hour dietary period to assure compliance. Subjects were measured by reverse-phase high-pressure liquid
collected all urine during the second 24-hour period of chromatography (HPLC) with precolumn derivatization
the low-NOX diet. Blood pressure was measured (2 to 3 and fluorescence detection using a modification of the
estimates at 5-minute intervals while subjects were qui- AccQ Tag system for amino acid analysis (Waters, Mil-
etly seated), and a blood sample was obtained at the end ford, MA, USA) as we described previously [25]. To
of the 48-hour dietary period, before 10 a.m., and after measure the endogenous NOS inhibitors asymmetrical
a fast of at least 12 hours, coincident with the end of dimethylarginine (ADMA) and symmetrical dimethylar-
the 24-hour urine collection. As discussed previously, ginine (SDMA), reverse-phase HPLC was used as de-
subjects come into NOX balance within 24 to 48 hours scribed by Anderstam, Katzarski, and Bergstrom with
of a controlled NOX diet [12]. minor modifications as we previously described [16, 25].
Recovery was 98 6 4% (on plasma spiked with 2.5
Sample collection and preparation mmol/L, N 5 4). Replicate measurements (N 5 5) of a
4 mmol/L sample gave a coefficient of variation of 5.7%.Urine was collected for 24 hours into sterile, dry, plas-
tic containers with 2% boric acid as an antibacterial Interassay variability (N 5 10 runs) for a plasma sample
spiked with 2.5 mmol/L was 9.2%. Because we estab-agent. Urine volumes were measured and samples ali-
quoted and stored frozen for later analysis. Blood sam- lished the HPLC method for ADMA after most of these
studies were undertaken, ADMA, SDMA, and n-mono-ples were taken into chilled tubes 1 ethylenediaminetet-
raacetic acid (EDTA) and were centrifuged at 48C, and methyl l-arginine (L-NMA) were measured in only 11
out of 13 of the CRD patients. Some of these measure-plasma was aliquoted, frozen, and stored at 2808C for
later analysis, except for endogenous methylarginine ments were made at varying time intervals (the average
was 7 months, range 0 to 14 months after the 24-houranalysis, in which heparin was used as the anticoagulant.
The plasma to be used for cGMP analysis was stored UNOXV collection, CRD subgroup). However all mea-
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Table 2. Blood pressure, renal function and 24 hour UNOXV and UcGMPV excretions in chronic renal disease patients and controls
BP mm HG
24 h CCr UprotV UNOXV UcGMPV
Systolic Diastolic mL/min mg/24h lmol/24h nmol/24h
CRD (N 5 13) 14267a 8264 3163a 359161055a 410656a 4736153b
CRD subgroup (N 5 6) 13769 7961 3366a 329261335a 322675a 5496163
Controls (N 5 9) 12065 7363 124621 63611 9146129 148651b
P value ,0.05 NS ,0.001 ,0.001 ,0.001 NS
a Different vs. control
b N 5 7
surements were made simultaneously in six of the CRD CRD. Low nonsignificance may have contributed to the
lack of statistical significance in this group, but given thepatients.
Plasma and urine sodium and potassium were measured fall in UNOXV, the predicted parallel relationship with
UcGMPV was clearly absent. In fact, there was no correla-by flame photometer. Creatinine concentrations were done
by colorimetric assay of the Janovski complex (Sigma kit tion between UcGMPV and UNOXV in control (r2 5 0.3895,
P 5 0.84) or CRD (r2 5 0.0038, P 5 0.74; Table 2).#555-A; Sigma Chemical Co., St. Louis, MO, USA).
All data were reported as mean 6 SE, and statistics Plasma creatinine was higher in CRD patients com-
pared with controls, reflecting a loss of renal clearancewere by paired and unpaired t-test and one-way analysis
of variance (ANOVA). Statistical significance was de- in the CRD group (Table 3). Plasma NOX was not signifi-
cantly higher in the CRD group. The increased plasmafined where P , 0.05.
cGMP was at the borderline of significance (P 5 0.05),
and plasma citrulline values were elevated versus con-
RESULTS
trols. Plasma arginine concentrations were similar in con-
Demographics and clinical characteristics of the study trols and CRD patients (Table 3), whereas PADMA and
population are presented in Table 1. The groups were PSDMA were elevated in CRD versus controls. Since plasma
of comparable age and body surface area (BSA), and levels of L-NMA were not detectable in most samples,
the average creatinine clearance in the CRD patients they are not reported. Although the average plasma cre-
was approximately 25% of control. The causes of CRD atinine and ADMA values were elevated in the CRD
were varied, with five individuals having diabetic ne- group, as shown in Figure 1, there was no correlation
phropathy, three with various glomerulonephritides (one between individual plasma values of creatinine and
status postnephrectomy), one with biopsy-proven pri- ADMA in the CRD patients.
mary focal segmental glomerulosclerosis, one with a soli-
tary kidney, one with chronic interstitial nephritis, one
DISCUSSIONwith obstructive nephropathy, and one with Wegener’s
granulomatosis. CRD patients were proteinuric, whereas A majority of patients with CRD suffer from hyperten-
sion, irrespective of the etiology of their renal disease.controls had normal urine protein excretion (Table 2).
Systolic blood pressure was higher in CRD patients ver- While hypertensive nephrosclerosis accounts for approx-
imately 20 to 25% of all diagnoses leading to ESRD,sus controls at the end of the 48-hour study period (Table
2) despite the fact that 12 out of 13 CRD patients were patients with ESRD from diabetic nephropathy (35% of
all ESRD and nearly 50% of our CRD patients) alsotaking one or more antihypertensive medications at the
time of study (Table 1). Urinary excretion of NOX over usually have hypertension [17–19]. Uncontrolled hyper-
tension has been associated with stroke and cardiovascu-24 hours was significantly lower in the CRD group com-
pared with the controls, and since intake was similar, lar morbidity and mortality, and contributes greatly to
morbidity in CRD patients, many of whom are diabeticthe endogenous NO production was much lower in CRD
patients than controls. As shown in Table 2, the values and thereby likely to have accelerated coronary artery
and atherosclerotic vascular disease [20].of 24-hour UNOXV, UcGMPV, protein excretion, and creati-
nine clearance were similar in the entire CRD group Blood pressures were significantly higher in our clini-
cally euvolemic CRD patients versus controls, despiteand the subgroup of CRD patients (N 5 6) in whom all
measurements were made contemporaneously. The 24- the fact that 12 out of 13 were on antihypertensive ther-
apy, suggesting a persistent hypertensive stimulus otherhour urinary excretion of cGMP was not measured in
every subject because of analytical problems, but in than fluid overload. NO deficiency has been implicated
as a potential cause of high blood pressure in CRD, andseven CRD patients and seven controls, the 24-hour
UcGMPV was not statistically different, although numeri- animal data suggest that net renal NO deficiency occurs
and is pathogenic. For example, chronic dietary argininecally the values were increased approximately 200% in
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Table 3. Plasma chemistry of CRD patients and controls
Parginine Pcitrulline PADMA PSDMAPCr PNOX PcGMP
mg/dL lmol/L pmol/mL lmol/L
CRD N 5 13 3.160.3a 62615 1562 6768b 6367ab 1.2660.30ac 0.6060.11ac
CRD subgroup N 5 6 3.060.4a 45612 1362 — — 1.4560.50 0.6060.13a
Controls N 5 9 0.860.1 3565 862 68610 3063 0.4060.10 0.1460.04
a Different vs. control
b N 5 9
c N 5 10
likely to be true if “total NO” and “hemodynamically
active NO” always change in parallel. The contribution
of the low levels of endothelial and intrarenal NO is
likely to be overwhelmed by the high level of production
from sites such as cerebellum, which do not have any
obvious hemodynamic impact. Thus, although our obser-
vation of reduced 24-hour UNOXV may reflect a deficiency
of “hemodynamically active” NO in CRD, this measure-
ment alone is merely suggestive.
Other measures that may also provide insight were
examined in the present study. For example, plasma NOX
values are unchanged in CRD, which most likely reflects
a combination of reduced total NO production and re-
duced renal clearance. In ESRD patients on dialysis, we
find that plasma NOX values are high (because of a com-
Fig. 1. Regression analysis showing lack of a relationship between plete loss of renal clearance) despite the low total NO
plasma asymmetrical dimethylarginine (ADMA) and plasma creatinine production [24, 25]. Unfortunately, therefore, plasma NOXlevels in 10 chronic renal disease (CRD) patients (r 2 5 0.03).
levels, even when obtained under conditions of dietary
NOX control, do not give “stand-alone” information
about NO production, particularly when renal function
is impaired. The plasma cGMP levels (a major secondsupplementation is renoprotective in a range of CRD
messenger of NO) were borderline high in CRD versusmodels, including ablation of renal mass, ureteral ob-
controls, and there was no correlation between 24-hourstruction, and cyclosporine-induced renal damage [1, 21].
UcGMPV and UNOXV, although UcGMPV showed an anomo-Chronic experimental NOS inhibition in normal rats pro-
lous, nonsignificant tendency to rise in CRD. There areduces hypertension and kidney damage, the severity of
several reasons for cGMP not being a reliable index ofwhich increases with increasing levels of NOS inhibition
NO production: NO signals through other messengers.[5]. Chronic NOS inhibition [22] and endogenous NOS
cGMP is also a second messenger to atrial natriureticdeficiency [23] accelerate the rate of progression of renal
peptide. Tissue, rather than plasma, levels of cGMP cor-ablation-induced CRD. Direct evidence of low intrarenal
relate with NO deficiency [26]. Therefore, the cGMPNOS activity and NOS expression has been reported in
level in body fluids is not readily interpretable in thethe 5/6 ablation model of progressive CRD [7, 8].
context of “hemodynamically active NO” production.The finding that 24-hour NOX output is low in our
We anticipate reduced arginine synthesis in CRD sinceCRD patients suggests that total systemic NO production
the kidney (a major site of endogenous arginine produc-is also low in humans with impaired renal function. This
tion) is failing [1]. This is supported by the finding thatis the first observation in subjects on controlled low NOX
citrulline levels (the precursor of arginine [3]) are mark-intake, an essential feature of the experimental design
edly elevated in CRD, which may reflect reduced citrullineif one attempts to use 24-hour NOX excretion as a mea-
to arginine conversion as well as reduced renal clearance.sure of total NO production [12]. Thus, we have estab-
However, these indirect indicators are not compellinglished that total NO production is uniformly low in pa-
evidence of a selective reduction in vascular/renal NOtients with CRD because of a variety of causes. The
production. Plasma levels of the endogenous NOS inhibi-assumption that is widely promulgated in the literature
tor ADMA are reported to rise in CRD in humans andis that low total NO production (from UNOXV) reflects
in rats [27, 28], and ESRD patients [26, 27], because itlow cardiovascular/renal NO production, the “hemody-
namically active” pool of NO. Unfortunately, this is only has been suggested to reduce renal clearance [2], although
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